在AD模型中,FAAH抑制通过自恢复对抗神经炎症
Federica Armeli1, Roberto Coccurello2,3, Giacomo Giacovazzo2,4
1Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, 04100 Latina, Italy.
International journal of molecular sciences
|November 27, 2024
概括
用URB597增加内分泌大麻素水平减少了阿尔茨海默氏症的发生.
科学领域:
- 神经科学是一个神经科学.
- 细胞生物学 细胞生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 神经炎症是阿尔茨海默病 (AD) 的一个关键特征.
- 内分泌大麻素显示出对抗神经炎症的潜力.
- 自机制可能参与AD的发病.
研究的目的:
- 为了研究是否通过URB597增加内分泌胺基调,可以在AD的细胞和动物模型中重新平衡自机制.
- 评估URB597在减少AD病理方面的治疗潜力.
主要方法:
- 使用微质培养物治疗了转基因小鼠的粉样β (Aβ25-35) 和Tg2576.
- 用URB597作为脂肪酸胺基酸酶 (FAAH) 抑制剂,以增加安纳米德水平.
- 评估了微质极化,细胞因子表达,粉样斑块负荷和自标志物 (BECN1,ATG7,LC3,SQSTM1/p62,ULK1通路).
主要成果:
- URB597治疗使微质偏向抗炎性表型,增加BDNF和Nrf2表达.
- 在URB597治疗的小鼠中,粉样蛋白斑块的数量和面积有所减少.
- 在Tg2576小鼠中恢复了自,由增加的BECN1,ATG7,LC3,SQSTM1/p62和ULK1通路激活证明.
结论:
- 用URB597增加内分泌胺基调可以抵消神经炎症,并减少AD模型中的粉样蛋白病理.
- 通过mTOR/ULK1依赖途径,URB597重新平衡了自.
- 内分类药物通过调节自来代表阿尔茨海默病的有前途的治疗策略.
相关概念视频
Alzheimer's Disease: Treatment
165
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
165
Alzheimer's Disease: Overview
448
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
448


